Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 8/20 | 0.57 |
| ▸ | HTR3A | P46098 | 7/20 | 0.53 |
| ▸ | NTSR1 | P30989 | 10/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4093036 | 0.91 | HRH4 (0.54) | HRH4HTR3ANTSR1ALDH1A1KDM4E | |
| SCHEMBL4095784 | 0.90 | NTSR1 (0.50) | HRH4NTSR1ALDH1A1MAPTPAX8 | |
| SCHEMBL4095281 | 0.85 | NTSR1 (0.49) | HRH4NTSR1ALDH1A1MAPTPAX8 | |
| SCHEMBL4095451 | 0.84 | NTSR1 (0.69) | HTR3ANTSR1ALDH1A1KDM4EMAPT | |
| SCHEMBL4091432 | 0.83 | NTSR1 (0.64) | HRH4HTR3ANTSR1ALDH1A1KDM4E | |
| SCHEMBL4754337 | 0.82 | NTSR1 (0.43) | HRH4HTR3ANTSR1ALDH1A1KDM4E | |
| SCHEMBL4094967 | 0.81 | IDE (0.50) | NTSR1ALDH1A1KDM4ECASP1CASP7 | |
| SCHEMBL4085145 | 0.81 | NTSR1 (0.65) | HRH4HTR3ANTSR1ALDH1A1KDM4E | |
| SCHEMBL4088803 | 0.80 | NTSR1 (0.48) | HRH4NTSR1ALDH1A1CASP1MAPT | |
| SCHEMBL4085177 | 0.80 | NTSR1 (0.48) | HRH4NTSR1ALDH1A1CASP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| WO-2008157500-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008157500-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | CNR2, CNR1, GPR18 | HRH4 14/4885HTR3A 637/4885NTSR1 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.